FFA
SYRS

Farther Finance Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Farther Finance Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20
Closed -$79 – 3622
2023
Q3 		$79 Hold
20
– – ﹤0.01% 2553
2023
Q2 		$63 Hold
20
– – ﹤0.01% 2454
2023
Q1 		$53 Buy
+20
New +$78 ﹤0.01% 2315

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Farther Finance Advisors's SYRS Position: Q4 2023 in Review

Farther Finance Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2023, closing a stake of 20 shares — an estimated $79 sold.

Farther Finance Advisors first reported a position in SYRS in Q1 2023 and held it in 3 quarters. The position peaked at $79 in Q3 2023. 58 funds tracked by Wall St. Rank hold SYRS as of Q4 2023.

  • Farther Finance Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Farther Finance Advisors sold 20 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $79.
  • Farther Finance Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 3 quarters.
  • Farther Finance Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $79 in Q3 2023.
  • 58 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Farther Finance Advisors's 13F filing for Q4 2023, filed 15 Feb 2024.